<p>The Indian drug regulator's subject expert committee has recommended emergency use approval for Zydus Cadila's three-dose <a href="http://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">Covid-19</a> vaccine, CNBC-TV18 <a href="https://twitter.com/CNBCTV18Live/status/1428622962400264200" target="_blank">reported</a> on Friday, citing sources.</p>.<p>The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, <em>CNBC-TV18</em> said in a tweet.</p>.<p>The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6% in a late-stage trial of more than 28,000 volunteers nationwide.</p>.<p>If approved, Zydus Cadila's vaccine will be the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin.</p>.<p>Zydus Cadila and India's drug regulator did not immediately respond to a <em>Reuters </em>request for comment.</p>.<p><strong>Check out DH's latest videos:</strong></p>
<p>The Indian drug regulator's subject expert committee has recommended emergency use approval for Zydus Cadila's three-dose <a href="http://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank">Covid-19</a> vaccine, CNBC-TV18 <a href="https://twitter.com/CNBCTV18Live/status/1428622962400264200" target="_blank">reported</a> on Friday, citing sources.</p>.<p>The committee added that Zydus needs to submit additional data for the 2-dose regimen of its vaccine, <em>CNBC-TV18</em> said in a tweet.</p>.<p>The generic drugmaker, listed as Cadila Healthcare Ltd, applied for the authorisation of the vaccine ZyCoV-D on July 1, based on an efficacy rate of 66.6% in a late-stage trial of more than 28,000 volunteers nationwide.</p>.<p>If approved, Zydus Cadila's vaccine will be the second home-grown shot to get emergency authorisation in India after Bharat Biotech's Covaxin.</p>.<p>Zydus Cadila and India's drug regulator did not immediately respond to a <em>Reuters </em>request for comment.</p>.<p><strong>Check out DH's latest videos:</strong></p>